Clinical trials: B Chronic Lymphocytic Leukemia
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to…
- Trial name
- NCT05424822
- Testing
- JNJ-80948543
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia
The purpose of this study is to confirm the efficacy and safety of fludarabine phosphate administered with dose increasing in 6 cycles (1 cycle: 5 treatment days every 28 days) in untreated chronic lymphocytic leukemia (CLL)…
- Trial name
- NCT00220311
- Testing
- Fludarabine Phosphate (Fludara)
- Volunteers
- 10 people
- Sponsor
- Genzyme, a Sanofi Company
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT819 in Subjects With B-cell Malignancies
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia.
- Conditions
- Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04629729
- Testing
- FT819, Cyclophosphamide, Fludarabine
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fate Therapeutics
Lymphocytic Leukemia, Chronic
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-line induction treatment with…
- Trial name
- NCT00718549
- Testing
- Cladribine, Cyclophosphamide, Rituximab
- Where
- 6 sites in Belarus, Poland
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
CLL, Solid Tumor, Adult
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
The goal of this clinical trial is to test the safety and preliminary efficacy of a new drug, KLS-1, in adults with different types of solid tumors and chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06506643
- Testing
- Zinc-64 Aspartate
- Where
- 2 sites in Ukraine
- Volunteers
- 36 people
- Sponsor
- Vector Vitale LLC
Chronic Lymphocytic Leukemia
Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis
This project will attempt to validate the utilization of a stable isotope kinetic biomarker (KineMarkerTM) as a predictive test for disease progression in early stage chronic lymphocytic leukemia (CLL).
- Trial name
- CRC011 (NCT00481858)
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- KineMed
Advanced Hematologic Malignancies
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokinetics.
- Trial name
- NCT01344707
- Testing
- 4SC-202
- Where
- 3 sites in Germany
- Volunteers
- 36 people
- Sponsor
- 4SC AG
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy…
- Conditions
- Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
- Trial name
- NCT05618028
- Testing
- ABBV-525
- Where
- 39 sites in United States, Australia and 8 more
- Volunteers
- 78 people
- Sponsor
- AbbVie
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
The main purpose of this study is to evaluate the effects of repeat dosing of ibrutinib on the single-dose pharmacokinetics (PK) of oral contraceptives (OC - ethinylestradiol [EE] and levonorgestrel [LN]), the cytochrome P450…
- Trial name
- NCT03301207
- Testing
- Ibrutinib, OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg, Bupropion
- Where
- 4 sites in Poland, Spain
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
The purpose of this study is to evaluate the safety, tolerability, dose-limiting toxicities (any harmful effect of a drug) (DLT), maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and preliminary clinical activity of…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell
- Trial name
- NCT02454270
- Testing
- Part 1 (Dose Escalation): Duvortuxizumab, Part 2 (Dose Expansion): Duvortuxizumab
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 59 people
- Sponsor
- Janssen Research & Development, LLC
Solid Malignancies, Non-Hodgkin's Lymphoma
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
The purposes of this study are to determine: the largest dose of AQ4N that can be safely given once a week for three weeks out of a 4 week cycle the side effects of AQ4N when given on the above schedule how much AQ4N is in the…
- Trial name
- NCT00090727
- Testing
- AQ4N
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novacea
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
The purpose of this study is to determine if the experimental drug, SG2000 is safe and tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia whose standard treatment did…
- Trial name
- NCT02034227
- Testing
- SG2000
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Spirogen
Chronic Lymphocytic Leukemia
Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients
Patients will have immune cells collected and then expanded outside of the body. Patients will receive an infusion of a large number of expanded immune cells. There will be three dose levels studied.
- Trial name
- NCT00058656
- Testing
- Infusion of Activated & Expanded Autologous T Cells
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Xcyte Therapies
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients.
- Conditions
- Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent
- Trial name
- NCT03853616
- Testing
- MB-CART19.1
- Where
- 9 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Miltenyi Biomedicine GmbH
Lymphocytic Leukemia, Chronic
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
This study will evaluate the efficacy and safety of rituximab in combination with chemotherapy (fludarabine and cyclophosphamide) in participants with B-cell CLL.
- Trial name
- NCT02533401
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 9 sites in Argentina, Venezuela
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL with or without the 17p deletion or TP53 mutation, including those who have received prior treatment…
- Trial name
- VENICE I (NCT02756611)
- Testing
- Venetoclax
- Where
- 67 sites in United States, Austria and 19 more
- Volunteers
- 258 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04282018
- Testing
- BGB-10188, Zanubrutinib, Tislelizumab
- Where
- 24 sites in Australia, China
- Volunteers
- 97 people
- Sponsor
- BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or…
- Trial name
- NCT04155710
- Testing
- IOV-2001, Low dose IL-2, High dose IL-2
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Lymphoma, Non-Hodgkin
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic…
- Trial name
- NCT04434196
- Testing
- CC-99282, Obinutuzumab
- Where
- 15 sites in United States, Austria and 2 more
- Volunteers
- 16 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia
Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia
- Trial name
- NCT01109264
- Testing
- Bendamustine hydrochloride injection, Chlorambucil
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.